Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 10 December 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Fructose and lactose intolerance and malabsorption testing

A study published ahead of print in the Alimentary Pharmacology & Therapeutics examines the relationship between fructose and lactose intolerance with symptoms in functional gastrointestinal disorders

News image

The association of fructose and lactose intolerance and malabsorption with the symptoms of different functional gastrointestinal disorders remains unclear.

Professor Wilder-Smith and colleagues from Switzerland investigated the prevalence of fructose and lactose intolerance and malabsorption, and their association with clinical gastrointestinal as well as non-clinical gastrointestinal symptoms in functional gastrointestinal.

In addition, the team examined the outcome of dietary intervention.

The research team demonstrated fructose and lactose intolerance and malabsorption in 1372 functional gastrointestinal disorders patients in a single center using breath testing.

Results were correlated with clinical symptoms in different functional gastrointestinal disorders Rome III subgroups.

The doctors assessed that the effectiveness of a targeted saccharide-reduced diet after 6–8 weeks.

Intolerance prevalence across all functional gastrointestinal disorders was 60% to fructose, 51% to lactose, and 33% to both.

Malabsorption occurred in 45%, 32% and 16% respectively.

Adequate symptom relief was achieved in 80% of intolerant patients
Alimentary Pharmacology & Therapeutics

The research team found that there were no differences in intolerance or malabsorption prevalence between functional gastrointestinal disorders subgroups.

Functional gastrointestinal disorders symptoms correlated with symptoms evoked during testing, but not with malabsorption.

The team of doctors found that non-clinical gastrointestinal symptoms occurred more commonly in patients with intolerances.

Methane breath levels were not associated with constipation using several cut-off thresholds.

The research team noted that adequate symptom relief was achieved in 80% of intolerant patients, irrespective of malabsorption.

Fructose and lactose intolerances are common in functional gastrointestinal disorders and associated with increased non-clinical gastrointestinal symptoms, but not with specific functional gastrointestinal disorders subtypes.

Professor Wilder-Smith's team concluded, "Symptoms experienced during breath testing, but not malabsorption, correlate with functional gastrointestinal disorders symptoms.

"Effective symptom relief with dietary adaptation is not associated with malabsorption."

"Mechanisms relating to the generation of clinical gastrointestinal and non-clinical gastrointestinal symptoms due to lactose and fructose in functional gastrointestinal disorders need to be explored further."

Aliment Pharmacol Ther 2013: DOI: 10.1111/apt.12306
12 April 2013

Go to top of page Email this page Email this page to a colleague

 09 December 2016 
Use of GI alarm features for colorectal cancer diagnosis
 09 December 2016 
Emergency department use by IBD patients
 09 December 2016 
PPI regimens for upper GI bleeds
 08 December 2016 
Preterm birth in women with IBD
 08 December 2016 
Precision medicine in IBD
 08 December 2016 
Intestinal tuberculosis vs Crohn's disease
 07 December 2016 
Iron deficiency in ulcerative colitis
 07 December 2016 
IBD source of information and patient education
 07 December 2016 
End-of-rotation resident transition and in-hospital mortality
 06 December 2016 
Anti-TNF therapy for IBD
 06 December 2016 
Crohn's disease and thyroid cancer risk
 06 December 2016 
IBD Disability Index in restorative proctocolectomy
 05 December 2016 
Reducing hospitalization in IBD
 05 December 2016 
Disease mangement in IBD
 05 December 2016 
New biomarkers for IBD diagnosis
 02 December 2016 
Hep E in acute liver failure
 02 December 2016 
Occurrence and severity of alcoholic hepatitis
 02 December 2016 
Food antigen in active eosinophilic esophagitis
 01 December 2016 
Iron deficiency in anemic ulcerative colitis patients
 01 December 2016 
Prognostic factors after paracetamol-induced liver failure
 01 December 2016 
Factors that influence colorectal cancer screening findings
 30 November 2016 
Certolizumab pegol in Crohn's disease
 30 November 2016 
Genetic risk of Crohn's in chronic granulomatous disease
 30 November 2016 
Rifaximin in diarrhea-predominant IBS
 29 November 2016 
Assessing liver steatosis
 29 November 2016 
Treating Zenker's diverticulum
 29 November 2016 
Colorectal cancer surveillance in ulcerative colitis
 28 November 2016 
Complications in celiac disease
 28 November 2016 
Monitoring IBD with mobile technology
 28 November 2016 
Reducing warfarin-related upper GI bleeds
 25 November 2016 
Metal vs plastic stents for pancreatic cancer surgery
 25 November 2016 
Yoga and IBS therapy 
 25 November 2016 
Colorectal cancer screening issues
 24 November 2016 
Partner burden in celiac disease
 24 November 2016 
Fusobacterium nucleatum for colorectal cancer prognosis
 24 November 2016 
PPIS and gastric cancer risk
 23 November 2016 
Quality assurance standards for colonoscopy
 23 November 2016 
Diagnosing autoimmune pancreatitis
 23 November 2016 
Readmissions in cirrhosis
 22 November 2016 
Bile acid diarrhea in function bowel disorder with diarrhea
 22 November 2016 
Fatigue in IBD
 22 November 2016 
PPIs and C. diff in ICU 
 21 November 2016 
Pain after endoscopic resection of gastric tumors
 21 November 2016 
Antivirals and chemotherapy in Hep C patients with cancer
 21 November 2016 
Financial incentives and colorectal cancer screening
 18 November 2016 
Colorectal cancer risk and self-reported family history
 18 November 2016 
Ustekinumab in Crohn’s disease
 18 November 2016 
Antivirals and chemotherapy in Hep C patients with cancer
 17 November 2016 
Liver-related specialty care in patients with Hep C
 17 November 2016 
Risk of overweight in infants
 17 November 2016 
Moderate alcohol consumption and NAFLD
 16 November 2016 
PPI therapy in liver disease
 16 November 2016 
Education in Gastroenterology fellowship
 16 November 2016 
Paternal preconceptional use of anti-TNF-α agents
 15 November 2016 
Novel treatment of NASH 
 15 November 2016 
Contraceptives and ulcerative colitis
 15 November 2016 
Physician perspectives on Hep C management
 14 November 2016 
Cardiovascular risk in NAFLD 
 14 November 2016 
Vit D and NAFLD
 14 November 2016 
Malignancy risk in IBD 

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us